Pre-Experimental: A Multi-Phase Clinical Trial to Assess the Efficacy and Safety of a Standardized, Full-Spectrum, THCP/CBDP-Fortified Cannabis Oil (Seshat's Oil) in Patients with Advanced Solid Tumors

While anecdotal claims have popularized high-THC cannabis oils like Rick Simpson Oil (RSO) for cancer treatment, their use is undermined by hazardous production methods and a lack of clinical evidence. Conversely, a substantial body of preclinical research demonstrates the antineoplastic properties of cannabinoids and supports the therapeutic superiority of full-spectrum extracts (the "entourage effect"). The recent discovery of novel phytocannabinoids, such as delta9-tetrahydrocannabiphorol (THCP) with its significantly higher CB1 receptor affinity, presents an opportunity to develop a rationally engineered, next-generation therapeutic agent. Objective: This paper outlines a comprehensive, multi-phase clinical trial protocol designed to definitively assess the safety and efficacy of a standardized, GMP-manufactured, full-spectrum cannabis oil fortified with THCP and CBDP (Investigational Product IP-X, "Seshat’s Oil") as an adjunctive therapy for patients with advanced, treatment-refractory solid tumors.